PedAM
Pediatric Disease Annotations & Medicines
| bacteremia | ||||
| Disease ID | 893 |
|---|---|
| Disease | bacteremia |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:16) C0009450 | infection | 71 C0021311 | infections | 37 C0032285 | pneumonia | 33 C0015967 | fever | 18 C0025289 | meningitis | 15 C0029443 | osteomyelitis | 10 C0007642 | cellulitis | 6 C0149778 | soft tissue infection | 4 C0014236 | endophthalmitis | 3 C0004659 | bacteriuria | 3 C0085437 | bacterial meningitis | 2 C0017658 | glomerulonephritis | 1 C0012739 | disseminated intravascular coagulation (dic) | 1 C0023885 | liver abscesses | 1 C0011570 | depression | 1 C0004623 | bacterial infections | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1799983 | 18827745 | 4846 | NOS3 | umls:C0004610 | BeFree | Endothelial nitric oxide synthase G894T (GLU298ASP) polymorphism is associated with hypotension in patients with E. coli bacteremia but not in bacteremia caused by a gram-positive organism. | 0.002638474 | 2009 | NOS3 | 7 | 150999023 | T | G |
| rs414171 | 20484391 | 1154 | CISH | umls:C0004610 | GAD | [When all five single-nucleotide polymorphisms (SNPs) (at positions -639, -292, -163, +1320, and +3415 all relative to CISH) within the CISH-associated locus were considered together in a multiple-SNP score, we found an association between CISH genetic variants and susceptibility to bacteremia, malaria, and tuberculosis (P=3.8x10(-11) for all comparisons), with -292 accounting for most of the association signal (P=4.58x10(-7)).] | 0.002638474 | 2010 | CISH;MAPKAPK3 | 3 | 50612068 | A | T |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:13) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0004610 | amikacin | D000583 | 37517-28-5 | bacteremia | MESH:D016470 | therapeutic | 319355 | ||
| C0004610 | ampicillin | D000667 | 69-53-4 | bacteremia | MESH:D016470 | therapeutic | 15332717 | ||
| C0004610 | azithromycin | D017963 | 83905-01-5 | bacteremia | MESH:D016470 | marker/mechanism | 11049784 | ||
| C0004610 | carbenicillin | D002228 | 4697-36-3 | bacteremia | MESH:D016470 | therapeutic | 6366126 | ||
| C0004610 | cefmenoxime | D015281 | 65085-01-0 | bacteremia | MESH:D016470 | therapeutic | 3264831 | ||
| C0004610 | cefotaxime | D002439 | 63527-52-6 | bacteremia | MESH:D016470 | therapeutic | 10897142 | ||
| C0004610 | ceftazidime | D002442 | 78439-06-2 | bacteremia | MESH:D016470 | therapeutic | 16918060 | ||
| C0004610 | ciprofloxacin | D002939 | 85721-33-1 | bacteremia | MESH:D016470 | therapeutic | 8295423 | ||
| C0004610 | daptomycin | D017576 | 103060-53-3 | bacteremia | MESH:D016470 | therapeutic | 17005801 | ||
| C0004610 | nafcillin | D009254 | 147-52-4 | bacteremia | MESH:D016470 | therapeutic | 6968176 | ||
| C0004610 | phenylephrine | D010656 | 59-42-7 | bacteremia | MESH:D016470 | therapeutic | 7604996 | ||
| C0004610 | piperacillin | D010878 | 61477-96-1 | bacteremia | MESH:D016470 | therapeutic | 3521269 | ||
| C0004610 | vancomycin | D014640 | 1404-90-6 | bacteremia | MESH:D016470 | therapeutic | 17060545 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D016470 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D016470 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D016470 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D016470 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |